October 6, 2009
Sanofi-aventis, a leading global pharmaceutical company, agrees to acquire Fovea Pharmaceuticals, a privately held French research and development biopharmaceutical company.
It was recently announced that Willkie client Sanofi-aventis, a leading global pharmaceutical company, agreed to acquire Fovea Pharmaceuticals, a privately held French research and development biopharmaceutical company, for a total enterprise value of up to €370 million. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to ocular diseases. The deal was handled by partners Laurent Faugérolas and Stéphane Sabatier, and associates Julie Herzog, Vanessa Zecchinel and Mélanie Martin. Antitrust aspects of the deal were handled by partner Jacques Philippe Gunther and associate Adrien Giraud.